| Year |
Citation |
Score |
| 2016 |
Cofield SS, Fox RJ, Tyry T, Salter AR, Campagnolo D. Disability Progression After Switching from Natalizumab to Fingolimod or Interferon Beta/Glatiramer Acetate Therapies: A NARCOMS Analysis. International Journal of Ms Care. 18: 230-238. PMID 27803638 DOI: 10.7224/1537-2073.2014-113 |
0.314 |
|
| 2016 |
Charles-Schoeman C, Lee YY, Shahbazian A, Wang X, Elashoff D, Curtis JR, Navarro-Millán I, Yang S, Chen L, Cofield SS, Moreland LW, Paulus H, O'Dell J, Bathon J, Bridges SL, et al. Improvement in HDL Function in Early Rheumatoid Arthritis Patients Treated with Methotrexate Monotherapy or Combination Therapy in the TEAR Trial. Arthritis & Rheumatology (Hoboken, N.J.). PMID 27483410 DOI: 10.1002/Art.39833 |
0.331 |
|
| 2016 |
Liu Y, Morgan C, Hornung L, Tyry T, Salter AR, Agashivala N, Belletti DA, Kim E, Fox RJ, Cofield SS, Cutter GR. Relationship between symptom change, relapse activity and disability progression in multiple sclerosis. Journal of the Neurological Sciences. 362: 121-6. PMID 26944131 DOI: 10.1016/J.Jns.2016.01.034 |
0.314 |
|
| 2015 |
Charles-Schoeman C, Wang X, Lee YY, Shahbazian A, Navarro-Millán I, Yang S, Chen L, Cofield SS, Moreland LW, O'Dell J, Bathon J, Paulus H, Bridges SL, Curtis JR. Association of Triple Therapy with Improvement in Cholesterol Profiles over Two Year Follow-up in the TEAR Trial. Arthritis & Rheumatology (Hoboken, N.J.). PMID 26606398 DOI: 10.1002/Art.39502 |
0.332 |
|
| 2015 |
Nickerson M, Cofield SS, Tyry T, Salter AR, Cutter GR, Marrie RA. Impact of multiple sclerosis relapse: The NARCOMS participant perspective. Multiple Sclerosis and Related Disorders. 4: 234-40. PMID 26008940 DOI: 10.1016/J.Msard.2015.03.005 |
0.335 |
|
| 2014 |
Salter AR, Marrie RA, Agashivala N, Belletti DA, Kim E, Cutter GR, Cofield SS, Tyry T. Patient perspectives on switching disease-modifying therapies in the NARCOMS registry. Patient Preference and Adherence. 8: 971-9. PMID 25045254 DOI: 10.2147/Ppa.S49903 |
0.322 |
|
| 2014 |
Bhanushali MJ, Gustafson T, Powell S, Conwit RA, Wolinsky JS, Cutter GR, Lublin FD, Cofield SS. Recruitment of participants to a multiple sclerosis trial: the CombiRx experience. Clinical Trials (London, England). 11: 159-66. PMID 24686106 DOI: 10.1177/1740774513517184 |
0.322 |
|
| 2014 |
Curtis JR, Wright NC, Xie F, Chen L, Zhang J, Saag KG, Bharat A, Kremer J, Cofield S, Winthrop K, Delzell E. Use of health plan combined with registry data to predict clinical trial recruitment. Clinical Trials (London, England). 11: 96-101. PMID 24346611 DOI: 10.1177/1740774513512185 |
0.336 |
|
| 2014 |
Boers M, Singh JA, Cofield SS, Bridges SL, Moreland LW, O'Dell JR, Curtis JR. OP0202 Omeract Method of Combined Reporting of Benefit and Harm Applied to the TEAR Trial Annals of the Rheumatic Diseases. 73: 139-139. DOI: 10.1136/Annrheumdis-2014-Eular.1954 |
0.332 |
|
| 2013 |
O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL, Ranganath VK, Moreland LW. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis and Rheumatism. 65: 1985-94. PMID 23686414 DOI: 10.1002/Art.38012 |
0.336 |
|
| 2013 |
Curtis JR, McVie T, Mikuls TR, Reynolds RJ, Navarro-Millán I, O'Dell J, Moreland LW, Bridges SL, Ranganath VK, Cofield SS. Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial. The Journal of Rheumatology. 40: 572-8. PMID 23588939 DOI: 10.3899/Jrheum.120715 |
0.329 |
|
| 2013 |
Navarro-Millán I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL, Chen L, Cofield SS, Dell'Italia LJ, Moreland LW, O'Dell JR, Paulus HE, Curtis JR. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis and Rheumatism. 65: 1430-8. PMID 23460074 DOI: 10.1002/Art.37916 |
0.32 |
|
| 2012 |
Lindsey JW, Scott TF, Lynch SG, Cofield SS, Nelson F, Conwit R, Gustafson T, Cutter GR, Wolinsky JS, Lublin FD. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics. Multiple Sclerosis and Related Disorders. 1: 81-6. PMID 25876935 DOI: 10.1016/J.Msard.2012.01.006 |
0.314 |
|
| 2012 |
Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis and Rheumatism. 64: 2824-35. PMID 22508468 DOI: 10.1002/Art.34498 |
0.337 |
|
| 2012 |
Wolinsky J, Narayana P, Nelson F, Datta S, Cofield S, Cutter G, Conwit R, Gustafson T, Lublin F. The CombiRx Trial: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Participants with Relapsing-Remitting Multiple Sclerosis – Clinical Outcomes (PL02.003) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.Pl02.003 |
0.344 |
|
| 2012 |
Fox R, Hornung L, Cofield S, Cutter G. Relationship between Symptom Worsening, Relapse Activity and Disease Progression in Patients with Multiple Sclerosis (P05.094) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P05.094 |
0.3 |
|
| 2010 |
Inusah S, Sormani MP, Cofield SS, Aban IB, Musani SK, Srinivasasainagendra V, Cutter GR. Assessing changes in relapse rates in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 1414-21. PMID 20810517 DOI: 10.1177/1352458510379246 |
0.35 |
|
| 2003 |
Dumur CI, Dechsukhum C, Ware JL, Cofield SS, Best AM, Wilkinson DS, Garrett CT, Ferreira-Gonzalez A. Genome-wide detection of LOH in prostate cancer using human SNP microarray technology. Genomics. 81: 260-9. PMID 12659810 DOI: 10.1016/S0888-7543(03)00020-X |
0.461 |
|
| Show low-probability matches. |